002030.SZ
Daan Gene Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 5.39
−3.75%Year over year
Reported trailing growth
- Revenue
- -10.4%
- EBITDA
- —
- EBIT
- -74.8%
- EPS
- -77.0%
- Free cash flow
- -56.2%
- Operating cash flow
- -12.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -60.2%
- EBITDA
- +37.9%
- EBIT
- +29.4%
- Net income
- +19.5%
- EPS
- +19.7%
- Free cash flow
- -68.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026